Vivek Ramaswamy bags $100M in risk capital to back his latest PhIII gamble at Dermavant — while Urovant dives into gene therapy
Just a few days after closing on a $330 million deal with GlaxoSmithKline to reel in a Phase III-ready drug for the crowded R&D field of psoriasis and atopic dermatitis, Vivek Ramaswamy’s Dermavant inked a $100 million financing deal to help pay for the next step in the clinic.
And that’s not all. The biotech financier also brought in another key player for his Roivant umbrella organization, recruiting an investment chair from NEA. And another one of his companies — Urovant — just in-licensed a gene therapy for overactive bladders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.